NCT06912282 Bilateral Single-Electrode VO Combined With STN-DBS for Treating Meige Syndrome
| NCT ID | NCT06912282 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huashan Hospital |
| Condition | Meige Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-03-06 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-03-06 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Meige syndrome is a rare and debilitating movement disorder characterized by blepharospasm, oromandibular dystonia, and cervical muscle contractions, often refractory to pharmacological therapies. Deep brain stimulation (DBS), initially developed to treat essential tremor and Parkinson's disease, has been explored in recent years as a potential treatment for various dystonias, including Meige's syndrome. This clinical study aims to evaluate the safety and efficacy of bilateral single-electrode ventralis oralis (VO) nucleus stimulation combined with subthalamic nucleus deep brain stimulation (STN-DBS) in patients with Meige syndrome.
Eligibility Criteria
Inclusion Criteria: * Must meet the clinical diagnostic criteria for Meige syndrome * Only includes patients with: Blepharospasm-type Meige syndrome and Blepharospasm with lower jaw muscle dystonia-type * All patients must have undergone at least one year of systematic and standard treatment prior to surgery Exclusion Criteria: * History of neurological diseases other than Meige syndrome * Severe cognitive impairment * Severe psychiatric disorders
Frequently Asked Questions
Who can join the NCT06912282 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Meige Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06912282 currently recruiting?
Yes, NCT06912282 is actively recruiting participants. Visit ClinicalTrials.gov or contact Huashan Hospital to inquire about joining.
Where is the NCT06912282 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06912282 clinical trial?
NCT06912282 is sponsored by Huashan Hospital. The trial plans to enroll 20 participants.